Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure, and metabolism.
about
The Impact of Anti-Epileptic Drugs on Growth and Bone MetabolismEpigenetic Mechanisms in Bone Biology and Osteoporosis: Can They Drive Therapeutic Choices?Impact of antiepileptic drugs on bone health: Need for monitoring, treatment, and prevention strategiesIntravenous levetiracetam in critically ill children with status epilepticus or acute repetitive seizures.Histone deacetylase inhibition destabilizes the multi-potent state of uncommitted adipose-derived mesenchymal stromal cellsHistone deacetylases in skeletal development and bone mass maintenance.Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts.Exposure to CYP3A4-inducing and CYP3A4-non-inducing antiepileptic agents and the risk of fractures.Hdac-mediated control of endochondral and intramembranous ossificationAntiepileptics and bone health.Women and epilepsy.Effects of Oxcarbazepine and Levetiracetam on Calcium, Ionized Calcium, and 25-OH Vitamin-D3 Levels in Patients with EpilepsyEpigenetic Mechanisms Regulating Mesenchymal Stem Cell Differentiation.Levetiracetam treatment does not result in broken bonesAntiepileptic drug use and rates of hip bone loss in older men: a prospective study.Do lamotrigine and levetiracetam solve the problem of using sodium valproate in women with epilepsy?Bone loss associated with use of antiepileptic drugs.Epilepsy in the elderly: Special considerations and challenges.Epilepsy in the elderly: facts and challenges.Influences of bone and mineral metabolism in epilepsy.HDACi: cellular effects, opportunities for restorative dentistry.Bone health in adults with epilepsy.The problem of osteoporosis in epileptic patients taking antiepileptic drugs.Epigenetic modulation of dental pulp stem cells: implications for regenerative endodontics.Markers of bone turnover in patients with epilepsy and their relationship to management of bone diseases induced by antiepileptic drugs.Effect of switching hepatic enzyme-inducer antiepileptic drug to levetiracetam on bone mineral density, 25 hydroxyvitamin D, and parathyroid hormone in young adult patients with epilepsy.The Histone-Deacetylase-Inhibitor Suberoylanilide Hydroxamic Acid Promotes Dental Pulp Repair Mechanisms Through Modulation of Matrix Metalloproteinase-13 Activity.Antiepileptic drugs and high prevalence of low bone mineral density in a group of inpatients with chronic epilepsy.HDAC inhibitor LMK‑235 promotes the odontoblast differentiation of dental pulp cells.Phenytoin and sodium valproate but not levetiracetam induce bone alterations in female mice.
P2860
Q26739054-58C7C463-1DAB-4005-9541-19ADE6B1BDBEQ26741198-613DD413-8AD5-4FBD-B679-4266C9D07656Q28074005-626F1DBD-976C-4A25-8422-7F604C603AFBQ34160934-A2E6B728-BA26-4469-89CF-B3C13DD03518Q34475885-4C4A85A4-9180-40C8-B16F-01FA8B007C23Q34612849-9E2A016C-B707-47E5-A484-701D9030C533Q34810920-C32F64C5-B29D-4F28-A0B1-60AA0DB31CB8Q35120734-AB0E0ABA-6413-44E5-B728-081F3BE1D986Q35556841-8F946105-F53C-4B04-93FE-52B3339CA70BQ36059549-522C4C29-20F2-44ED-8075-DA4925B3BD35Q36287145-82D0AF6F-11BD-44D8-9FAE-3FACA97DB043Q36514350-F5992CFB-7C87-4E8D-B21D-A2EB64BA2712Q36613056-C31ED775-220E-4821-A5C9-FFD83E30D37CQ36804592-2B533F81-6472-4547-8390-CC0B0BD3AFC0Q37178973-C2C0489B-892E-40BF-972F-94C18F717FCDQ37186130-04028D5D-F6F9-4DEB-8217-655577B7450BQ37702229-A61AAA70-06A9-4F19-AC47-60D9AD2ACDE2Q37725946-0C5E4D0A-6152-489F-9B85-64E6F4518B5CQ37818528-1B247401-7251-49EB-A6EA-D764C2885803Q37842459-E9447C4A-74E0-4306-93EE-2650851161EEQ37871246-3528DDF3-9080-4487-BCC9-C782563544C4Q37895322-DDD6B995-96B3-4B09-8A77-FA54545A783FQ38211406-F779BEF6-5BC3-4CB0-944C-2551436DF747Q38502939-AACDA6A5-8696-4686-BC3B-EDE8B4276B89Q38640619-345137F3-E94D-4879-AD94-97363CE070CBQ44505154-AC02A8C8-C450-4CB2-A291-0049B5F57EEDQ46280254-B896B626-53C1-41A6-BB71-20FA5998D417Q46313804-898FA953-6528-4EDD-9B02-21D0B5459702Q47401089-B28CCE5A-5CB9-47B7-841B-0C41E8B20F4BQ51143850-56097928-323B-4826-B96C-611B1B5E4E3D
P2860
Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure, and metabolism.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Levetiracetam, phenytoin, and ...... ss, structure, and metabolism.
@ast
Levetiracetam, phenytoin, and ...... ss, structure, and metabolism.
@en
Levetiracetam, phenytoin, and ...... ss, structure, and metabolism.
@nl
type
label
Levetiracetam, phenytoin, and ...... ss, structure, and metabolism.
@ast
Levetiracetam, phenytoin, and ...... ss, structure, and metabolism.
@en
Levetiracetam, phenytoin, and ...... ss, structure, and metabolism.
@nl
prefLabel
Levetiracetam, phenytoin, and ...... ss, structure, and metabolism.
@ast
Levetiracetam, phenytoin, and ...... ss, structure, and metabolism.
@en
Levetiracetam, phenytoin, and ...... ss, structure, and metabolism.
@nl
P2093
P2860
P50
P1433
P1476
Levetiracetam, phenytoin, and ...... ss, structure, and metabolism.
@en
P2093
Finn P Reinholt
Gunhild Melhus
Lene B Solberg
Lise Sofie H Nissen-Meyer
Rune Jemtland
Sigrid Svalheim
Sjur Reppe
P2860
P304
P356
10.1111/J.1528-1167.2007.01176.X
P577
2007-07-18T00:00:00Z